The incidence of breast cancer (BC) and soft tissue sarcoma (STS) in the Israeli general population is 97/10 5 women and 1.5/10 5 persons. It is expected that 1.5/10 5 ϫ 49/10 5 of the women in the general population will have both BC and STS. Methods: A retrospective search of 1350 adult STS patient files that were recorded between 1995 and 2005. Results: One hundred thirty-four patients with STS had multiple primary malignancies. BC was observed in 27/64 patients (42%) before/after the STS: BC-first in 19/27, BC-later in 8/27. Of 19 with BC-first the STS was related to radiotherapy in 2, and to lymphedema in 1. Of 8 STS-first, only 1 got chemotherapy before BC. Median interval between first to second malignancies was 6.9 years for BC-first, and 3.8 for BC-later. The incidence of BC among all patients with STS-first followed by a second malignancy is 8/58 (14%), or 27/890 (3%) of all women STS-patients in the registry. The incidence of STS among the BC patients was low, and most of our cases were therapy unrelated. Median survival for BC-first was 305 months, versus 213 for STS-first. Conclusions: BC and STS may naturally occur in the same individual. The etiology for this phenomenon is unclear. Practically, BC screening in patients with STS is warranted.
C o-occurrence of multiple primary malignancies (MPM) in a single individual is well documented, 1 and may be attributed to one of several factors: incidental occurrence, host susceptibility factors (eg, inherited predisposition or immunodeficiency), exposure to common carcinogenic environmental factors, clustering of different risk factors in the same individual, or chemotherapy associated. Breast cancer (BC) survivors are known to be at risk for developing second primary tumors. The risk of second primary malignancies was studied in a French cohort of 4416 one-year survivors of a BC. Excluding second primary BC and nonmelanoma skin cancer, an incidence of 4.4% was found for developing a second primary malignancy 2 with the tumors most commonly encountered being soft tissue sarcomas (STC), leukemia, melanoma, kidney, ovary, and uterine tumors, especially in women diagnosed under age 40 years or those who received radiotherapy. 2 In another study, the 15-year contralateral BC rate was 12%, whereas second malignant neoplasm the rate was 6%. 3 Several mechanisms may underlie this unusual clustering of tumors in a single individual with a previous diagnosis of BC. Tumors such as acute myeloid leukemia, lung, esophagus, and endometrial cancer are specifically attributable to BC therapy or adjuvant hormonal therapy (eg, tamoxifen). 4, 5 Similarly STS of the chest wall may develop in BC survivors in the irradiated fields. 6 Contralateral BC and ovarian cancer in BC survivors may stem from harboring germ-line mutations in high penetrance cancer susceptibility genes such as BRCA1/BRCA2. 7, 8 Some of the associations between MPM in BC survivors remain established but unaccounted for by these known mechanisms (eg, malignant melanoma). 9 STS have also been reported to be associated with MPM at a rate of 7.5%. 10 Most of the cases of MPM in STS occurred incidentally, and with no relation to previous therapies 10 , whereas in a handful of patients this co-occurrence was associated with the presence of a germ line mutation in the p53 gene in the context of the Li-Fraumeni syndrome. 11 Specifically the rates of BC were never reported in an unselected cohort study of STS cases, analysis that forms the basis of this report.
PATIENTS AND METHODS
The study is based on a retrospective search of STS-database for patients with STS and at least 1 other primary tumor that occurred either before or following the diagnosis of STS. Of 1350 adult STS patients who were referred, diagnosed, or treated at our center between 1995 and 2005, we retrieved only patients with STS and BC at any time of their lives, with or without other primary malignancies. The data gathered on each patient included demographic data and clinically relevant data (eg, disease course, therapeutic measures, prognostic factors, survival). Patients with primary breast sarcoma were not included in the analysis unless they had also primary breast carcinoma. Statistical work-up included descriptive statistics, t test, and survival analysis by Kaplan-Mayer method. P values of less than 0.05 were considered statistically significant.
RESULTS
Overall, 134 patients ͓64 women (47.8%); 70 (52.2%) men͔, of a total of 1350 patients diagnosed with STS were also diagnosed with at least one additional primary malignancy (9.92%). Of the 64 females with STS and an additional malignancy, 27 (27/64 ϭ 42%) had breast carcinoma, before or after the diagnosis of STS. All the patients were white Jewish (Ashkenazi or Sephardic) in origin. Their age at time of diagnosis of either first malignancy, eg, BC or STS, ranged from 16 to 87 years (median 56). In 19/27 (70.4%) of these patients BC was diagnosed as the first primary tumor (age at BC-diagnosis 35-87 years, median 56 years), and in the remaining 8, BC was diagnosed after the diagnosis of STS (age at STSdiagnosis 16 -70 years, median 49 years) as second or third primary tumor. Invasive ductal carcinoma was diagnosed in 24/27 patients, ductal carcinoma in situ in 2, and medullary in 1. Table 1 shows the sequence of malignant events in all 27 study participants. 
BC-First (N ‫؍‬ 19)
Median age of patients with BC was 56 years (35-87 years). Risk factors, which were reported by the patients before the development of the BC as the first malignancy, included a history of cancer in the family in 5 cases: 2 patients with a family history of BC, 1 patient with colorectal cancer in 2 second degree relatives, 1 patient whose mother had a brain tumor, and 1 patient whose brother had lung cancer. Infiltrating ductal carcinoma was evident in 16/19 patients, ductal carcinoma in situ in 2 cases, and medullary carcinoma in 1 case. The disease stage was locoregional in 18 women and metastatic in one. Sixteen underwent breast conserving surgery and 3 mastectomy. Radiation therapy to the breast was delivered in 14 cases, and systemic chemotherapy (cyclophosphamide ϩ methotrexate ϩ 5-fluorouracil or doxorubicin ϩ cyclophosphamide ϩ 5-fluorouracil) was administered in 6 cases. Hormonal therapy was prescribed to all 9 hormone-receptor positive tumors. In 2 cases, the STS were the third tumors, which followed breast cancer and skin cancer. For the whole group of BC-first cases, STS were diagnosed after a median latent period of 83 months (8.6 -432 months). STS types included mainly leiomyosarcoma (3 uterine, 1 limb), followed by angiosarcoma (2 breast, 1 arm), liposarcoma of trunk, and others (Table 1) . Time for diagnosis of the sarcoma after BC and overall survival are depicted in Figure 1 . Interestingly, of 19 patients with first primary BC, the sarcoma appeared in the RT field only in 2, and in 1 it appeared in a lymphedematous ipsilateral arm. In the other patients there were no relation between therapy given for the BC and the location of the subsequent STS.
STS-First (N ‫؍‬ 8)
Median age of patients with STS-first was 48 years (16 -70 years) . Three of the patients had dermatofibrosarcoma protuberans, 2 had pleomorphic sarcoma, and the others liposarcoma, fibrosarcoma, and spindle cell sarcoma. Five sarcomas originated in a limb, 1 in the breast and 2 in the trunk. In one case the STS was associated with pregnancy (patient LB). All the STS were localized and underwent complete resection. Adjuvant radiation therapy was delivered in 2 cases, whereas chemotherapy in 1 case. The median age for the development of BC was 61 years (39 -80 years), after a latency of 71 months (6.5-568 months). In 7 patients, the BC was the second tumor, in one case-the third, after STS and melanoma. Two patients had STS followed by metachronous bilateral BCs. One patient had STS, BC, and then skin cancer. All the BCs were either localized or locoregional, and treated according to the local standards. Two BCs were hormone receptor positive. Time to BC and overall survival of this group are depicted in Figure 1 . Interestingly, of 8 patients with first primary STS, only 1 got chemotherapy before 
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Median interval between first and second malignancy was 6.9 years (0.7-31 years) when the BC was diagnosed first, and 3.8 years (0 -47 years) when the BC was the second. Time-to-second-malignancy graphs are depicted in Figure 1 . Median survival for BC-first patients was 305 months, versus 213 months for STS-first patients. The survival curves are depicted in Figure 1 . No significant differences were found for 10 years, 20 years, and median survival values of BC-first versus STS-first cases.
We compared the survival of the patients in this series, grouped all together, whether BC preceded or followed STS, with the survival of 58 female patients (age 18 -87 years, median 54 years) with limb STS treated by limb sparing surgery and radiation therapy. Female patients with STS-BC pair of malignancies survived longer than female patients with STS alone. The difference in survival did not reach statistical difference, but showed a mild trend towards significance (P ϭ 0.089). However, when sex-and-age matched cases of limb STS were compared with STS and BC cases, the survival curves were similar.
DISCUSSION
The phenomenon of multiple primary malignancies in patients with STS has already been reported. 10, 14, 15 Our group was the first to report on this phenomenon. 10 We have shown that 7.5% of our sarcoma patients developed other malignant neoplasms either before or after the diagnosis of STS. In most of the cases, the second malignancy was unrelated to therapy given for the first tumor. 10 Tateishi et al 14 reported an incidence of 9% of patients with STS and a second primary malignancy. The risk of multiple malignancies seemed to be impacted by age at the time of diagnosis of the first tumor and by the histologic type of myxofibrosarcoma. Fernebro et al 15 searched the Southern Swedish Cancer Registry for patients with STS and an additional malignancy before or after the STS. The most common cancer types that developed before the STS diagnosis were breast cancer, prostate cancer, and malignant melanoma. The most frequent tumor types after the STS diagnosis were prostate cancer and colorectal cancer. Twenty-seven out of the 818 patients (3.3%) had both BC and STS. Most of them had BC-first.
Our current series focuses on the association of BC and STS in the same patients. Our data point to the fact that the occurrence of BC in association with STS is higher than expected according to the theoretical co-occurrence of the 2 diseases in the general population.
The present database consists of 2 distinctive groups of BC and STS patients: BC-first followed by STS or vice versa. Most of the cases belonged to the BC-first group. One may claim that chemotherapy given for the STS when it is the first malignancy, leads to suppression of BC growth via various mechanisms. In the current series, however, only one STS was treated by chemotherapy, and the BC was diagnosed 1.7 years later.
The precise mechanisms underlying this association are presently unclear, but a putative list of some of the factors that may contribute to the observed increased rates of BC in STS patients include: disease-related immunosuppression, genetic factors, firstline treatment, age at first treatment, vulnerability of breast tissue, hormonal factors, chemotherapy-induced premature menopause, and smoking. It is conceivable that a common putative gene mutation might be responsible for both tumors, as reported for breast and ovarian cancers, 7, 8 or suggested for breast and thyroid cancers, 16 breast and lung cancers, 17 or breast and melanoma. 9 One of the most plausible contributing factors is genetic susceptibility in the form of germ line mutations in cancer susceptibility genes. Noteworthy, in a large series of carriers of germ line mutations in BRCA1 and BRCA2 genes that confer an inherited predisposition to BC, there was no overall increase in the rates of STS. 18, 19 Genetic analyses were reported in one study 20 that focused on 23 unrelated individuals from families with one case of sarcoma and at least one case of BC. These families were classified according to their conformity to the criteria defining the Li-Fraumeni syndrome (LFS), Li-Fraumeni like syndrome (LFLS), and hereditary breast/ovarian cancer (HBOC). Genotyping for germ line mutations in the TP53 (for LFS and LFS-like), BRCA1 and BRCA2 genes (for HBOC), was carried out for all participants. Germ line TP53 mutations were identified in 3/23 (13%) of cases, including one LFS and 2 Li-Fraumeni-like families. Three cases (13%), including one with a TP53 mutation, carried a BRCA2 mutations. 21 Thus, the majority of cases with STSBC remained unaccounted for by mutations in the known cancer susceptibility genes. In our series, 1 patient with BC-first carried BRCA1 mutation, and had a family history of BC, bladder, ovarian, and large bowel cancers. Seven other patients had a record of various cancers occurring in 1-2 family members.
Most of the STS cases in BC patients in our series were unrelated to RT because STS seemed away from the irradiated volume. Similarly all the BCs in patients with former STS were probably unrelated to the sarcoma therapy. The majority of literature data supports the link between the therapies given for the first cancer as etiology in the development of the second malignancy.
The risk of posttreatment sarcoma in BC patients was studied in 122,991 Swedish women with a BC according to the Swedish Cancer Registry. A standardized incidence ratio of 1.9 for developing a STS after therapy to BC was found. The sarcomas were located in the breast region or on the ipsilateral arm in 63%. Angiosarcomas encountered for 35% of all STS. In a case-control study, angiosarcoma correlated significantly with lymphedema of the arm, but no correlation with radiotherapy was observed. For other types of sarcoma there was a correlation with the integral dose. 20 Other authors also found that most of the sarcomas in BC patients were directly related to previous radiation therapy fields. 22 The most well recognized association is with the postmastectomy, postirradiated lymphedematous arm, described by Stewart and Treves. 23 This is not a radiation-induced sarcoma because the lymphangiosarcoma develops both inside and outside of the irradiated field, in the edematous extremity.
Several types of sarcoma have been diagnosed in BC patients after breast/chest wall irradiation, including malignant fibrous histiocytoma, fibrosarcoma, osteosarcoma, and other. 24 Huang et al 25 evaluated the risk of STS in the vicinity of previously irradiated anatomic regions in women with breast carcinoma by using the Surveillance, Epidemiology, and End Results Program (SEER) data regarding 194,798 women who had been diagnosed with invasive breast carcinoma between 1973 and 1995. In SEER, women who were treated with RT as part of their initial treatment for breast carcinoma had a 16-fold increase in the risk of angiosarcoma and a 2-fold increase in the risk of other sarcomas. The increase was especially high in the chest wall/breast for any STS. A second cause for the development of angiosarcoma was the surgery-related lymphedema, or more intense surveillance in the women with breast carcinoma and a possible genetic link between sarcoma and breast carcinoma. 25 According to these authors, 25 on the basis of their findings, if one studies 10,000 women with breast carcinoma who either are treated or not treated with RT as a part of their initial treatment and then followed for 10 years, 21 and 7 STRs, respectively, might be expected. Approximately 15 cases of STR occurring per year in every 100,000 women treated with RT for breast carcinoma would be attributable to the RT, whereas only 6 cases of STS may be related to other causes. They estimated that the crude 5-year survival rate was approximately 32% for the 135 women with a second STR in their study, and the median survival time was only 25 months. 25 It is, however, likely that with advances in technology and improvement of RT technique the rate of RTinduced STS will decrease.
Cohen et al 26 evaluated 1499 children at age of less than 18 years at the time of diagnosis of STS, who survived for at least 1 year after the diagnosis. The risk of second malignancies was increased for all histologic types of childhood STS, and was particularly high among patients who received combined modality therapy. The risk of developing a subsequent malignancy was increased among children with rhabdomyosarcoma, fibromatous neoplasms, and other specified STS. Initial therapy with radiation and chemotherapeutic agents was associated with a significantly higher risk of second malignancies compared with surgery alone. Elevated risks for second malignancy were observed for acute myeloid leukemia, cutaneous melanoma, female breast cancer, and sarcomas of the bone and soft tissue. For only several children out of 1499, the pattern of multiple malignancies was consistent with a genetic syndrome. In most of the cases, the etiology for the second primary remained either previous therapy or unknown. 26 An interesting observation in our series was that the overall survival curves of BC-first and STS-first patients were superimposed. No matter which tumor grew first, the survival was identical. Similarly, we could not retrieve any data regarding the survival of BRCA2 carrier patients whether they had BC-first or BC after an ovarian cancer. In other diseases, such as Hodgkin lymphoma, the outcome of secondary solid tumors depends on tumor entity and is not different from that of primary solid tumors. However, lung cancer as a second malignancy was aggressive and fatal. 27 The observation that the survival curves were similar for BC-first or STS-first may support the notion that there is a common etiologic disorder, such as a mutated gene, that is responsible for the 2 tumors in patients with BC-STS pair of malignancies.
The survival of patients with STS and BC was similar to the survival of age and sex-matched control group with limb STS treated by limb sparing surgery and radiation therapy. This observation raised the idea of possible less aggressive BCs and less aggressive STSs that are associated with the syndrome of STS-BC, enabling the patients to survive longer. Indeed 3 out 8 patients with STS-first had dermatofibrosarcoma protuberans, which is eventually a low-grade sarcoma. However for BC-first patients (the majority of this series), the types of STS were aggressive by histologic characteristics, as in the limb-STS control group, but perhaps less aggressive by clinical behavior.
We could not retrieve any data regarding the survival of other tumor pairs linked to known mutations. In BRCA2, for example, ovarian cancer may follow BC and vice versa, but there is no data regarding the survival curves related to the 2 options. It has been reported, however, that BRCA mutation carriers with ovarian cancer lived significantly longer than noncarriers with the same tumor independently of age at diagnosis or stage of the disease. 28 In conclusion, BC and STS may naturally occur in the same individual, whereas the etiology for this phenomenon remained to be elucidated. The practical aspect of our observation is the need for BC screening in patients with a history of STS, as an integral part of their follow-up.
